Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery, Inflammatory Reaction After Neonatal Cardiac Surgery
Interventions: Inhaled Nitric Oxide, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 1 Day to 30 Days
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Traumatic Brain Injury
Interventions: Autologous HB-adMSCs, Normal Saline; Biological · Drug
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: pioglitazone, Placebo control; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 6 Years to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Type 2 Diabetes
Interventions: Lysulin; Dietary Supplement
Lead sponsor: Juraj Koska; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: AEVI-001, Placebo; Drug
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Wayne, Pennsylvania

Conditions: Alcohol Dependence
Interventions: RDC-0313, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Endometriosis
Interventions: Real stimulation VS Sham; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 64 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Lentivirus Infections, Acquired Immunodeficiency Syndrome
Interventions: Mesalamine (5-aminosalicylic acid, Apriso), Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia
Interventions: Oxytocin, Inactive placebo nasal spray; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Angioedema
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cocaine Dependence
Interventions: levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease, Metabolic Acidosis
Interventions: Sodium bicarbonate, Placebo; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: The Bronx, New York • Cleveland, Ohio

Conditions: HIV Infections
Interventions: SP01A; Drug
Lead sponsor: Samaritan Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 4 more

Conditions: Schizophrenia
Interventions: SEP-363856, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 35
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more

Conditions: Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
Interventions: sildenafil, placebo; Drug · Other
Lead sponsor: Marywood University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Healthy
Interventions: BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Subjective Tinnitus
Interventions: Conventional sound generator (SG), Placebo sound generator (placebo SG), Standard of Care (SC), Directive Counseling (DC); Device · Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 6
States / cities: Camp Pendleton, California • San Diego, California • Travis Air Force Base, California + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CTLA-4 Ig, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 45 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 9 more

Conditions: Osteo Arthritis Knee
Interventions: Geniculate Artery Embolization, Sham Procedure; Device · Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Woodbridge, Virginia

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions: Insulin, Placebo (Sterile diluent); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: Risperidone plus Placebo, Risperidone plus DMXB-A; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Depressive Disorder, Major
Interventions: saredutant (SR48968), paroxetine, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Healthy
Interventions: Methylphenidate, Triazolam, Project: EVO, Placebo; Drug · Other
Lead sponsor: Akili Interactive Labs, Inc.; Industry
Eligibility: 40 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity or Overweight
Interventions: Placebo, Enicepatide; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 44
States / cities: Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 37 more

Search by objective public record fields.

Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

The Effect of Lysulin on Glycemic Control and Advanced Glycation

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

ALK33-001: A Study of RDC-0313 Administered to Healthy Adults

Ear Electro-stimulation for Chronic Pelvic Pain

Mesalamine to Reduce T Cell Activation in HIV Infection

Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

Cognitive Remediation for Cocaine Dependence

Alkali Therapy in Chronic Kidney Disease

A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Does Sildenafil Increase Exercise Performance in Air Pollution?

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Tinnitus Retraining Therapy Trial

Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

Nicotinic Receptors and Schizophrenia

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes